Moving to the tumor context and considering the well-established role of RNASET2 in tumors and the tumor microenvironment (the latter including both the stromal and the immune compartments in tumors), together with its impact on the cancer therapy response, we suggest that RNASET2 can be envisaged as a marker for early tumor response, based on its alarmin-like actions, as well as a marker for induced anti-tumor immune response, following therapies potentially re-activating the immune system against tumor cells. The gene discussed is RNASET2; the disease is neoplasm.